PerkinElmer, Inc. (NYSE:PKI) has been given a consensus recommendation of “Hold” by the eighteen analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $72.85.

PKI has been the topic of several recent research reports. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Monday, January 8th. Robert W. Baird restated a “buy” rating and set a $72.00 target price on shares of PerkinElmer in a research report on Friday, October 20th. Citigroup restated a “buy” rating and set a $80.00 target price (up previously from $74.00) on shares of PerkinElmer in a research report on Tuesday, September 26th. ValuEngine downgraded PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Jefferies Group restated a “hold” rating and set a $70.00 target price on shares of PerkinElmer in a research report on Friday, October 20th.

PerkinElmer (PKI) traded up $1.27 during trading hours on Tuesday, hitting $78.89. The company’s stock had a trading volume of 448,700 shares, compared to its average volume of 560,511. The stock has a market capitalization of $8,750.00, a P/E ratio of 35.70, a P/E/G ratio of 1.90 and a beta of 0.77. PerkinElmer has a 12-month low of $50.59 and a 12-month high of $79.02. The company has a current ratio of 2.59, a quick ratio of 2.09 and a debt-to-equity ratio of 0.44.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.35%. PerkinElmer’s payout ratio is currently 12.67%.

In other news, Director Alexis P. Michas sold 5,000 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $73.18, for a total value of $365,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Andrew Okun sold 12,680 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00. Following the completion of the transaction, the insider now directly owns 25,121 shares in the company, valued at approximately $1,808,712. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,336 shares of company stock worth $6,114,917. Insiders own 2.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in PKI. Acrospire Investment Management LLC increased its stake in PerkinElmer by 185.7% in the second quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 1,300 shares during the last quarter. Waldron LP bought a new position in PerkinElmer in the third quarter valued at $200,000. Seaward Management Limited Partnership bought a new position in PerkinElmer in the third quarter valued at $202,000. Carret Asset Management LLC bought a new position in PerkinElmer in the second quarter valued at $210,000. Finally, Cubist Systematic Strategies LLC bought a new position in PerkinElmer in the second quarter valued at $269,000. 91.37% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/perkinelmer-inc-pki-receives-consensus-recommendation-of-hold-from-analysts-2/1809209.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.